Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy.
|Numero di pagine||7|
|Rivista||ClinicoEconomics and Outcomes Research|
|Stato di pubblicazione||Pubblicato - 2009|
- Markov model